The combination of anti-VEGF/VEGFR2 signaling inhibitors with checkpoint inhibitors has shown efficacy over standard-of-care treatment in multiple tumor types, including lung cancer [28], renal cell carcinoma [29,30,31], and hepatocellular carcinoma [32]. This evidence concerns the gene KDR and lung cancer.